• Reserpine (N1867): Practical Lab Protocol Guide

  2026-09-29

  Reserpine (SKU N1867) provides a high-purity research compound for neurotransmitter depletion research, antihypertensive mechanism studies, and neuropharmacology workflows. This guide addresses identity checks, DMSO-based preparation, storage, and troubleshooting; the material is for research use only and is not intended for diagnostic, therapeutic, or medical applications.

• PRKX Stabilizes PD-L1 in Gastric Cancer

  2026-09-29

  A 2026 study identifies PRKX as a regulator of an immunosuppressive gastric cancer subtype, linking PRKX phosphorylation of PD-L1 to YWHAE recruitment, reduced ubiquitination, and immune exhaustion. The work combines single-cell profiling, mechanistic experiments, patient biomarker analysis, and lipid nanoparticle delivery of PRKX-targeting siRNA to explain resistance to anti-PD-1 therapy.

• MK-2206: Contextual Akt Inhibition for Better Assays

  2026-09-28

  MK-2206 dihydrochloride enables selective Akt1/2/3 pathway interrogation, but its strongest experimental value emerges when phosphorylation, apoptosis, and metabolism are measured together. This article connects Akt-focused assay design with new insights into Wnt-driven O-GlcNAcylation and glycolytic rewiring.

• Dihydroartemisinin: Reading Drug Effects Over Time

  2026-09-28

  Dihydroartemisinin is more informative when researchers distinguish early biological responses from later effects on cell survival. This article uses a recent cabamiquine pharmacodynamics study to explain assay-design principles while clarifying what those findings do—and do not—tell us about Dihydroartemisinin.

• Cl-Amidine: PAD4 Assay Design Beyond IC50

  2026-09-27

  Cl-Amidine is a PAD4 inhibitor for probing how arginine citrullination shapes cellular responses. This guide connects enzyme inhibition to stronger assay design, careful interpretation of disease models, and a distinct mechanistic lesson from recent mitophagy research.

• Go 6983 (pan-PKC inhibitor): Cell Assays

  2026-09-26

  A scenario-based guide to using Go 6983 (pan-PKC inhibitor), SKU A8343, in cell viability, proliferation, and PKC signaling experiments. It covers potency, assay controls, handling, data interpretation, and practical product-selection criteria without treating biochemical potency as a cellular dose.

• Zoledronic Acid: From Cell Death to Translation

  2026-09-25

  A translational framework for studying Zoledronic Acid across tumor-cell apoptosis and bone disease models—while separating pathway hypotheses from demonstrated effects, improving assay interpretation, and avoiding common formulation and evidence pitfalls.

• Docetaxel (A4394): Practical Assay Design

  2026-09-25

  A scenario-driven guide to using Docetaxel (SKU A4394) in cell viability, proliferation, and cytotoxicity studies. Learn how its microtubule mechanism, handling characteristics, and literature context can inform dose selection, controls, and interpretation.

• QX77 and the Logic of Autophagy Assay Design

  2026-09-24

  QX77 is a molecular chaperone activator that can help researchers probe LAMP2A-linked chaperone-mediated autophagy and Rab11-associated trafficking. This article explains how to distinguish those effects from mitophagy, using a recent bronchopulmonary dysplasia study to sharpen assay design without implying that the pathways or disease applications are interchangeable.

• AMPK–SQSTM1 Feedback Under Metabolic Stress

  2026-09-24

  A 2024 study describes a double-positive feedback loop between AMPK and SQSTM1/p62 that coordinates energy-stress signaling with NFE2L2/NRF2 antioxidant responses. Its mechanistic model links lysosomal changes, KEAP1 degradation, and AMPK activation, helping explain how stressed cancer cells may sustain antioxidant defense and growth.

• Computational Hapten Design for Dual Mushroom-Toxin Sensing

  2026-09-23

  This study combines computationally informed hapten design with antibody development to create a fluorescent immunochromatographic assay for simultaneous detection of amatoxins and phallotoxins in mushrooms. Its strongest contribution is improved antibody recognition across related toxins, supporting sensitive screening while leaving confirmatory analysis and broader matrix validation important.

• Hexa His tag peptide for Clean Elution

  2026-09-23

  Hexa His tag peptide enables antibody-sparing recovery of 6X His fusion proteins from immunoprecipitation workflows. This practical guide covers competitive elution, concentration starting points, interaction-preserving conditions, and troubleshooting for cleaner protein purification and protein interaction analysis.

• Temafloxacin Combinations Against Mycobacterium avium

  2026-09-22

  This 1993 study evaluated clarithromycin, temafloxacin, and ethambutol against pigmented and non-pigmented Mycobacterium avium complex isolates using extracellular susceptibility and macrophage-based assays. Its key contribution was showing that drug interaction depended on the combination and strain phenotype, while the three-drug regimen produced the strongest intracellular bactericidal effect.

• Influenza Hemagglutinin (HA) Peptide for IP

  2026-09-22

  Influenza Hemagglutinin (HA) Peptide enables gentle, competitive elution of HA-tagged proteins for interaction, ubiquitination, and signaling studies. This workflow-focused guide shows how to apply the HA tag peptide to mechanistic experiments inspired by NEDD4L–PRMT5 research while improving recovery, specificity, and troubleshooting.

• Deoxycholic Acid Sodium Salt in NSCLC Assays

  2026-09-21

  Deoxycholic acid sodium salt provides a practical detergent option for preparing cell and tumor lysates used to study the SNORA38B–GAB2–AKT/mTOR axis. This workflow emphasizes assay-specific detergent strength, phosphoprotein preservation, and separate sample handling for protein, RNA, and immune profiling.

8616 records 1/575 page Next 12345 下5页 Last page